Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed COO
Appointed director
BridgeBio Pharma, Inc. (BBIO) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/18/2023 4 HOMCY CHARLES J (Director) has filed a Form 4 on BridgeBio Pharma, Inc.
Txns: Paid exercise price by delivering 1,301 shares @ $29.8, valued at $38.8k
Exercised 3,760 restricted stock units @ $0
08/18/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/18/2023 4 Kumar Neil (CEO and President) has filed a Form 4 on BridgeBio Pharma, Inc.
Txns: Paid exercise price by delivering 50,698 shares @ $29.8, valued at $1.5M
Sold 51,552 shares @ $28.5883, valued at $1.5M
Exercised 5,130 restricted stock units @ $0
Exercised 2,394 restricted stock units @ $0
Exercised 61,182 restricted stock units @ $0
Exercised 33,544 restricted stock units @ $0
08/17/2023 144 Form 144 - Report of proposed sale of securities:
08/17/2023 144 Form 144 - Report of proposed sale of securities:
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update - Announced consistently positive results from the Phase 3 ATTRibute-CM study of acoramidis in patients with transthyretin amyloid cardiomyopathy , including a highly statistically significant result observed on the primary endpoint with a Win Ratio of 1.8 , demonstrating a continued potentially best-in-class efficacy and well-tolerated safety profile, and a mean increase in annualized height velocity of 3.38cm/year with no treatment-related adverse events - Dosed the first participant in FORTIFY, a global Phase 3 study of BBP-418 in patients with limb girdle muscular dystrophy type 2I/R9 and met with the FDA to discuss the use of glycosylated alpha-dystroglycan levels as a surrogate endpoint; based on this ..."
07/26/2023 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
07/19/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
07/19/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/18/2023 144 Form 144 - Report of proposed sale of securities:
07/17/2023 8-K Quarterly results
05/18/2023 4 Kumar Neil (CEO and President) has filed a Form 4 on BridgeBio Pharma, Inc.
Txns: Paid exercise price by delivering 50,697 shares @ $14.09, valued at $714.3k
Sold 51,552 shares @ $14.0095, valued at $722.2k
Exercised 5,129 restricted stock units @ $0
Exercised 2,394 restricted stock units @ $0
Exercised 61,182 restricted stock units @ $0
Exercised 33,544 restricted stock units @ $0
05/18/2023 4 HOMCY CHARLES J (Director) has filed a Form 4 on BridgeBio Pharma, Inc.
Txns: Paid exercise price by delivering 1,300 shares @ $14.09, valued at $18.3k
Exercised 3,759 restricted stock units @ $0
05/18/2023 4 STEPHENSON BRIAN C (Secretary, Treasurer & CFO) has filed a Form 4 on BridgeBio Pharma, Inc.
Txns: Paid exercise price by delivering 20,572 shares @ $14.09, valued at $289.9k
Sold 24,424 shares @ $14.0095, valued at $342.2k
Exercised 1,710 restricted stock units @ $0
Exercised 778 restricted stock units @ $0
Exercised 24,193 restricted stock units @ $0
Exercised 947 restricted stock units @ $0
Exercised 17,368 restricted stock units @ $0
05/17/2023 144 Form 144 - Report of proposed sale of securities:
05/17/2023 144 Form 144 - Report of proposed sale of securities:
05/05/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/05/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/04/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/04/2023 8-K Quarterly results
05/04/2023 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
05/03/2023 144 Form 144 - Report of proposed sale of securities:
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/05/2023 144 Form 144 - Report of proposed sale of securities:
03/09/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Underwriting Agreement, by and among the Company, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Morgan Stanley & Co. LLC, as representatives of the several Underwriters listed on Schedule I thereto",
"Opinion of Goodwin Procter LLP regarding the issue of Common Stock being registered",
"BridgeBio Pharma Announces Proposed Public Offering of Common Stock",
"BridgeBio Pharma Announces Pricing of Public Offering of Common Stock"
03/09/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/06/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/06/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events",
"Corporate presentation, furnished herewith"
03/03/2023 4 STEPHENSON BRIAN C (Secretary, Treasurer & CFO) has filed a Form 4 on BridgeBio Pharma, Inc.
Txns: Sold 62,692 shares @ $10.9607, valued at $687.1k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy